In Brief: Taro Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceuticals: Plans to begin shipping private-label clotrimazole cream 1% for vaginal yeast infections in the first quarter of 1996. The company's generic equivalent to Schering-Plough's Gyne-Lotrimin was approved by FDA on Dec. 4, marking the second such ANDA to be cleared by the agency, following A.L. Labs' 1993 approval for clotrimazole. Taro also sells topical clotrimazole 1% cream, hydrocortisone .5% and 1% creams, tolnaftate 1% cream and miconazole 2% cream for the store-brand market...